Epitalon FDA Approval History

No FDA Approval Exists for Epitalon

Epitalon has no approved new drug application, no biologics license application, and no public investigational new drug filing in any FDA database. A search of Drugs@FDA, the FDA Orange Book, and the National Drug Code Directory returns zero results for "epitalon," "epithalon," or its chemical designation Ala-Glu-Asp-Gly [2]. The compound has never gone through the standard FDA drug-approval pipeline: preclinical IND-enabling toxicology, Phase I safety, Phase II dose-finding, Phase III key trials, and NDA review.

This absence is not an oversight. Epitalon was developed entirely within the Russian Federation's regulatory framework at the St. Petersburg Institute of Bioregulation and Gerontology during the 1990s and 2000s [1]. The Institute's research team, led by Professor Vladimir Khavinson, published clinical data in Russian journals and in Bulletin of Experimental Biology and Medicine, but no sponsor has ever filed the standardized safety and efficacy dossier that the FDA requires under 21 U.S.C. § 355. Without a U.S.-based sponsor willing to fund the multi-phase trial process (typically $1 billion to $2.6 billion per drug, according to a 2020 Tufts Center estimate), FDA review cannot begin [3].

What Is Epitalon and Where Did It Come From?

Epitalon is a four-amino-acid synthetic peptide (alanine-glutamic acid-aspartic acid-glycine) designed to mimic a fraction of the polypeptide complex extracted from bovine pineal gland called epithalamin. Khavinson's group at the St. Petersburg Institute synthesized the tetrapeptide in the late 1990s as a defined, reproducible alternative to the crude gland extract [1].

The proposed mechanism centers on telomerase activation. In a 2003 study of human fetal fibroblast and retinal pigment epithelium cell cultures, Khavinson and colleagues reported that epitalon induced telomerase activity in somatic cells that normally suppress the enzyme, potentially extending the replicative lifespan of those cells [1]. A separate arm of the same research program tracked 266 elderly patients in a 6-year observational protocol and reported lower cardiovascular mortality in the peptide-treated group compared to controls [1]. These findings, while frequently cited in longevity forums, have not been independently replicated in Western peer-reviewed journals with randomized, placebo-controlled, double-blind methodology.

The Russian Ministry of Health did grant epithalamin (the crude pineal extract predecessor) a limited pharmacopoeia listing for gerontological use, but this approval does not extend to epitalon and carries no reciprocal recognition with the FDA or EMA [4].

The FDA Approval Process Epitalon Has Not Entered

A peptide therapeutic must clear five sequential regulatory gates before reaching U.S. patients. Epitalon has not entered gate one.

Preclinical / IND-enabling stage. A sponsor conducts GLP-compliant toxicology, pharmacokinetics, and manufacturing characterization, then submits an IND application. The FDA has 30 days to place a clinical hold or allow dosing to proceed [2]. No IND for epitalon appears in the FDA's public clinical-hold database or in ClinicalTrials.gov.

Phase I. First-in-human dose-escalation in 20 to 80 healthy volunteers, measuring safety, tolerability, and pharmacokinetics. No such trial is registered.

Phase II. Dose-ranging efficacy in 100 to 300 patients with the target condition. No such trial is registered.

Phase III. Key efficacy in 1,000+ patients against placebo or active comparator. No such trial is registered.

NDA / BLA review. The FDA evaluates the complete data package. For peptides over 40 amino acids, a BLA through the Center for Biologics Evaluation and Research (CBER) may apply; for shorter synthetic peptides like epitalon, the Center for Drug Evaluation and Research (CDER) would typically review an NDA [2]. Neither pathway has been initiated.

A ClinicalTrials.gov search (May 2026) for "epitalon" OR "epithalon" OR "Ala-Glu-Asp-Gly" returns zero registered interventional studies in any country [5]. This means not only has no U.S. trial been conducted, but no foreign trial data meeting ICH-GCP standards exists that a sponsor could reference in a 505(b)(2) NDA submission.

Published Clinical Evidence: Scope and Limitations

The clinical literature on epitalon comes almost exclusively from Khavinson's group. The most-cited human study appeared in Bulletin of Experimental Biology and Medicine in 2003, describing outcomes in 266 patients aged 60 and older who received either epithalamin (the crude extract) or epitalon (the synthetic tetrapeptide) alongside standard care [1].

Key reported findings from that 6-year observation:

• Cardiovascular mortality in the treated group was 8.2% vs. 14.3% in controls
• Telomerase activation was documented in cell culture (not measured in vivo in the clinical subjects)
• The authors noted improved "bioregulation" markers, a concept specific to the Russian bioregulatory peptide framework that does not map directly to endpoints the FDA accepts for approval

Several methodological gaps limit the applicability of these results to a Western regulatory filing. The study was not randomized in a blinded fashion. Allocation concealment methods were not described. Intent-to-treat analysis was not reported. The primary endpoint was not pre-specified in a publicly registered protocol. According to the FDA's guidance on adequate and well-controlled studies (21 CFR 314.126), at least two adequate and well-controlled trials demonstrating a clinically meaningful effect are ordinarily required for approval [2]. Epitalon has zero trials meeting that standard.

Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine and principal investigator of the TAME (Targeting Aging with Metformin) trial, has stated: "Peptides with only open-label data from a single research group, no matter how intriguing, cannot substitute for the rigorous Phase III evidence regulators and clinicians need to recommend a therapy" [6].

Legal Status in the United States

Epitalon occupies a regulatory gray zone. It is not a controlled substance under the Controlled Substances Act, which means possession is not a federal crime. It is not an FDA-approved drug, which means it cannot be legally marketed with therapeutic claims for human use in the United States [2].

Most domestic vendors sell epitalon labeled "for research purposes only" or "not for human consumption." This labeling sidestep does not fully protect sellers or buyers. The Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. § 321) defines a "drug" as any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease [2]. If marketing materials, website copy, or social-media posts imply therapeutic intent, the FDA can classify the product as an unapproved new drug and pursue enforcement.

Import considerations. The FDA's Division of Import Operations can detain peptide shipments at the border under import alert if the product appears to be an unapproved drug intended for clinical use. Buyers ordering from overseas compounding sources or gray-market peptide suppliers face confiscation risk with no legal recourse.

State pharmacy board rules. Some states permit compounding pharmacies to prepare peptides under a physician's prescription through the 503A or 503B exemption pathway, but epitalon is rarely stocked by legitimate compounding pharmacies because no USP monograph or FDA-recognized compendial standard exists for it [7].

How Epitalon Compares to FDA-Approved Peptide Therapeutics

The FDA has approved dozens of peptide drugs through the standard NDA pathway. These approvals illustrate what the agency requires and what epitalon lacks.

Semaglutide (Ozempic, Wegovy). A 39-amino-acid GLP-1 receptor agonist. Novo Nordisk ran the SUSTAIN program (8 Phase III trials, >8,000 patients) and the STEP program (N=1,961 in STEP-1 alone) before receiving FDA approval for type 2 diabetes (2017) and chronic weight management (2021) [8]. Semaglutide's approval dossier included over 15,000 patient-years of safety data.

Tesamorelin (Egrifta). A 44-amino-acid growth hormone-releasing hormone analogue. Theratechnologies submitted two Phase III trials (N=816 combined) demonstrating visceral adipose tissue reduction in HIV-associated lipodystrophy before the FDA granted approval in 2010 [9].

Epitalon, by contrast, is a 4-amino-acid peptide with one 266-patient open-label observation and no Phase III program. The gap between its evidence base and the threshold for FDA approval is not incremental. It is structural.

What Would FDA Approval Require?

A sponsor seeking FDA approval for epitalon would need to complete the following minimum regulatory milestones:

1. Manufacture the peptide under current Good Manufacturing Practice (cGMP) conditions with a validated analytical method and stability program
2. Conduct IND-enabling GLP toxicology studies (28-day repeat-dose in two species, genotoxicity battery, reproductive toxicity if indicated)
3. File an IND and receive FDA clearance to proceed
4. Complete Phase I safety and pharmacokinetic profiling (single ascending dose, multiple ascending dose) in approximately 40 to 80 subjects
5. Identify a specific, measurable clinical endpoint the FDA considers approvable (telomere length alone has never served as a primary efficacy endpoint for any FDA-approved drug)
6. Run two adequate, well-controlled Phase III trials powered for that endpoint
7. Submit an NDA with the complete chemistry, manufacturing, controls (CMC), nonclinical, and clinical data package

Conservative industry estimates place this pathway at 8 to 12 years and $800 million to $2 billion in direct costs [3]. No pharmaceutical company or biotech sponsor has publicly announced plans to pursue this program for epitalon.

Safety Considerations Without FDA Oversight

Because epitalon has never undergone FDA-mandated safety review, several risks are either unknown or unquantified.

Purity and contamination. Research-grade peptides sold online are not manufactured under cGMP. Third-party certificate-of-analysis (COA) testing by groups like Janoshik or Vanta Bioscience has identified mislabeled peptides, bacterial endotoxin contamination, and sub-potency in gray-market products [10]. Without a USP monograph, there is no enforceable purity standard.

Long-term telomerase activation concerns. Telomerase is constitutively active in approximately 85% to 90% of human cancers [11]. Whether exogenous telomerase activation by a peptide bioregulator could promote occult tumor growth is an open question. The Khavinson 2003 study did not report cancer incidence data with sufficient follow-up to address this concern [1]. The National Cancer Institute notes that telomerase reactivation is a hallmark of malignant transformation [11].

Drug interactions. No formal drug-interaction studies have been conducted. Pharmacokinetic parameters (half-life, clearance, volume of distribution, protein binding) have not been characterized in humans using modern LC-MS/MS bioanalytical methods.

Immunogenicity. Peptide therapeutics can provoke anti-drug antibody responses. The FDA requires immunogenicity testing as part of every peptide NDA [2]. No such data exist for epitalon.

The European and International Regulatory Picture

Epitalon holds no marketing authorization from the European Medicines Agency (EMA). No European Public Assessment Report (EPAR) exists. A search of the EMA's Union Register of Medicinal Products returns no results for epitalon or epithalon [12].

In Russia, the crude pineal extract epithalamin received limited registration under the Russian pharmacopoeia for use in elderly patients, but this registration is distinct from epitalon (the synthetic tetrapeptide) and does not constitute approval by any Western regulatory body [4]. Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and Australia's Therapeutic Goods Administration (TGA) similarly have no filings for epitalon.

The peptide is not listed on the World Anti-Doping Agency (WADA) prohibited list as of 2026, though WADA's S2 category (peptide hormones, growth factors, and related substances) could potentially encompass compounds with demonstrated growth-hormone-axis or telomerase-modulating activity if evidence warranted inclusion [13].

Patients Considering Epitalon: A Clinical Reality Check

For patients encountering epitalon through anti-aging clinics or online peptide vendors, the clinical reality is straightforward. The peptide has no FDA approval, no Phase III data, no established dose, no validated endpoint, and no cGMP-manufactured commercial product. Any provider administering epitalon to patients is doing so entirely off-guideline, without the safety net of post-market pharmacovigilance, REMS programs, or FDA MedWatch adverse-event reporting infrastructure.

The Endocrine Society's 2019 clinical practice guideline on testosterone therapy provides a useful parallel: the Society explicitly recommends against unregulated "anti-aging" hormone therapies that lack adequate trial evidence, citing unquantified long-term risk [14]. The same principle applies to epitalon. Patients should ask any prescribing provider three questions: What is the FDA status? What Phase III trial supports this dose for my condition? What adverse events have been reported in controlled studies? For epitalon, the answer to all three is "none."